<< Back To Authors

Overview

Liz Highleyman

Liz is Science Editor for Cancer Health, POZ, Hep and Real Health. She has been a health journalist and medical editor for more than 20 years, covering HIV, viral hepatitis, cancer and other health issues.

Articles

illustration hologram figure in doctors hand

Treating Cancer Anywhere

The Food and Drug Administration may approve the next site-agnostic treatment in August.

Triple Combo for Pancreatic Cancer

A three-pronged approach could offer hope for people with hard-to-treat advanced pancreatic cancer.

Therapy for HPV Cancers

A new type of immunotherapy shows promising activity against cancers caused by human papillomavirus (HPV).

Immunotherapy for People With HIV

Could new cancer drugs restore immune responses against HIV?

Surgery for Metastatic Breast Cancer

Removal of the primary breast tumor may be warranted in women who respond well to targeted therapies.

The Microbiome Frontier

Changing gut bacteria to improve treatment response may be the next frontier in immunotherapy.

FDA OKs Keytruda for Initial Treatment of Advanced Head and Neck Cancer

First-line immunotherapy improved overall survival by around 20% to 40%, depending on PD-L1 level.

FDA Approves Polivy for Relapsed or Nonresponsive Lymphoma

Antibody-drug conjugate carries a chemotherapy drug directly to cancerous B cells.

Hot topics

Breast Cancer

Lung Cancer

Liver Cancer

Prostate Cancer

Cancer Treatment

Cancer Screening

Ovarian Cancer

Blood Cancers - Leukemia/Lymphoma/Multiple Myeloma

Women With BRCA-Positive Breast Cancer Can Safely Become Pregnant

Large international study sees no detrimental outcomes for mothers or babies.

Checkpoint Immunotherapies Show Promise for Liver Cancer

Keytruda showed modest benefits for people with this difficult-to-treat cancer, and combining Opdivo with Yervoy improved outcomes.

Keytruda Improves 5-Year Survival for People With Advanced Lung Cancer

The immunotherapy drug shows the most benefit for newly treated people with tumors that test positive for the PD-L1 biomarker.

More Evidence Supports Checkpoint Immunotherapy for People With HIV

Keytruda and Imfinzi showed response rates and safety profiles similar to those seen in HIV-negative people.

First KRAS Targeted Therapy Shows Promise for Lung and Colon Cancer

AMG 510 shrank tumors in half of lung cancer patients with a mutation thought to be “undruggable.”

Revlimid Reduces Risk That Smoldering Disease Will Progress to Multiple Myeloma

Around 90% of people treated with the immunomodulator did not develop cancer.

Kisqali Improves Survival in Premenopausal Women With Advanced Breast Cancer

Recently approved CDK4/6 inhibitor plus hormone therapy extends overall survival by about a third.

Cancer Drugs Given Fast Approval May Not Measure Up Over Time

Eighty percent of medications that receive accelerated approval don’t extend overall survival.


			Facebook

			Twitter

			Instagram

			Pinterest